Navigation Links
Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Date:10/1/2013

CORK, Ireland, Oct. 1, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) announced that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease at the upcoming Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place November 1 to 5 in Washington, D.C.

"Simeprevir's clinical profile has been characterized through a robust clinical development program including more than 3,700 patients," said Gaston Picchio, Disease Area Leader Hepatitis, Janssen. "The study results that will be presented at the AASLD Annual Meeting support the potential utility of simeprevir in a number of different hepatitis C patient populations."

Simeprevir was approved in Japan in September 2013 for the treatment of genotype 1 hepatitis C. In the U.S., the New Drug Application (NDA) filed by Janssen for simeprevir administered once daily in combination with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients was granted Priority Review designation by the Food and Drug Administration (FDA) in May. Simeprevir is also being studied in several interferon-free regimens using selected combinations of direct-acting antiviral agents with different mechanisms of action.

The data to be presented at the 2013 AASLD Annual Meeting include:

Poster Presentations: HCV Therapeutics: New Agents, Poster Hall, November 3, 8:00 a.m. - 5:30 p.m. (EST)

  • Simeprevir (TMC435) with peg-interferon alpha-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: Efficacy and safety in patient sub-populations in the PROMIS
    '/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
2. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
3. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
4. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
5. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
6. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
7. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
8. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
9. Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy
10. Bulgaria Launches Development of National Hepatitis Plan
11. Major Breakthrough in Hepatitis C Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)...  BC Technical, the nation,s leading non-OEM provider of ... leader in sales, service and installation of GE MRI ... to continue to expand their resources and inventory while ... "We are committed to driving higher ... president and CEO of BC Technical. "We set out ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and Markets ... Drug Pipeline Insight 2014" report to their offering. ... US is one of the largest segments of pharmaceuticals industry. ... rate, while the available therapies were unable to meet the ... the market for CNS disorder, especially over the past two ...
(Date:8/29/2014)... -- Research and Markets has announced the ... of Pharmaceutical Equipment Market in China, 2014-2018" report ... Trend Forecast of Pharmaceutical Equipment Market in ... pharmaceutical equipment industry in the aspects of ... business performance of domestic major enterprises, as well as ...
Breaking Medicine Technology:BC Technical Acquires Polaris Medical Imaging 2US CNS Disorders Drug Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
... SCHAUMBURG, Ill., Nov. 23 Sagent Pharmaceuticals, Inc., a privately-held ... announced that Jeffery M. Yordon, chief executive officer, founder and ... the 21st Annual Piper Jaffray Health Care Conference on Tuesday, ... York Palace Hotel in New York City, NY. , ...
... , , IRVINE, Calif., Nov. ... global infection prevention solution provider, announced today the ... Gloster Europe, a privately held developer of innovative ... Terms of the acquisition were not disclosed. ...
Cached Medicine Technology:ASP Announces Acquisition of Gloster Europe to Help Reduce Infections in Healthcare Facilities 2
(Date:9/2/2014)... At the 50th Annual Mr. Olympia Fitness ... exhibitor at the Las Vegas Convention Center South Hall, ... Booth #374 Sept 19th and 20th 10am-5PM. , ... exercise, diet and supplementation. They pride themselves on creating ... for all Prosupps customers to reach their personal health ...
(Date:9/2/2014)... Tuesday 2 September 2014: Digoxin may increase the ... by approximately 20%, according to results from the ROCKET ... Manesh Patel, director of interventional cardiology and catheterisation labs ... US. The findings suggest that caution may be needed ... studies are needed to confirm the observations. , Dr ...
(Date:9/2/2014)... 02, 2014 Aeroflow Healthcare, an industry ... Southeast, announced the opening of its new office to ... is: 310 Business Parkway, Suite D, Greer, SC 29651. ... patients with a more convenient location in the Greenville ... Healthcare and the physicians, hospitals and patients we serve, ...
(Date:9/2/2014)... Productive Dentist Academy, a dental ... State, has been named to Inc. Magazine’s 5000 list ... the third year in a row it has obtained ... astonishing 63 percent growth rate and increased revenues from ... increased its number of employees from eight to 25. ...
(Date:9/2/2014)... hosting is a great choice for webmasters to build ... suppliers and announced that Arvixe, Bluehost and JustHost are ... hard to find a good fast hosting supplier. Actually, ... uptime, server speed and customer support. People can get ... of Top10BestSEOHosting.com says. , Arvixe has a world-class data ...
Breaking Medicine News(10 mins):Health News:Prosupps, One of the Fastest Growing Supplement Companies, Celebrates a Success Milestone with Exhibiting at the 50th Annual 2014 Mr. Olympia’s Fitness & Performance Expo 2Health News:ROCKET AF trial suggests that digoxin increases risk of death in AF patients 2Health News:Aeroflow Healthcare Opens Office In Greer, SC To Service Greenville & Spartanburg Patients 2Health News:Dental Management Company Named to Fastest-Growing List Again 2Health News:Dental Management Company Named to Fastest-Growing List Again 3Health News:Top10BestSEOHosting.com Recommends Fast Web Hosting Suppliers 2
... patients undergoing team-based care do not save more ... other patients, but they are healthier, according to ... substantial financial burden on patients, payers and employers," ... administration, Penn State, and lead author of the ...
... issue of the Journal of Leukocyte Biology ... efficacy of the current tuberculosis vaccine. Specifically, a team ... I interferon, in which it improves the ability of ... bacterium known to cause tuberculosis. The researchers speculate that ...
... as an ingredient in sunscreen, researchers say , , THURSDAY, Feb. ... might offer some protection from skin cancer, and new research ... to be the mechanism by which caffeine is associated with ... associate professor of dermatology at the University of Washington in ...
... Feb. 26 The following release was issued today ... federal vaccine court ruled against three families claiming vaccines ... writers Robert F Kennedy, JR and David Kirby reported ... who regressed into autism following the MMR vaccine. Last ...
... 2010 Budget Must Complement Stimulus Policy Objectives, Not Undermine ... a new bipartisan letter from four U.S. House lawmakers ... eldercare funding, the Coalition to Protect Senior Care (CPSC) ... Reinvestment Act (ARRA) will help strengthen the nation,s long ...
... to save cancer patients, lives can also destroy their ... oncofertility has advanced the ability of doctors to preserve ... are diagnosed with cancer. Yet, many oncologists aren,t familiar ... A leading oncofertility researcher and a breast surgical oncologist ...
Cached Medicine News:Health News:Team-based diabetes care fetches more value for dollar 2Health News:New discovery gives tuberculosis vaccine a shot in the arm 2Health News:Caffeine May Offer Some Skin Cancer Protection 2Health News:Caffeine May Offer Some Skin Cancer Protection 3Health News:On the Heels of Court Ruling Denying Autism-Vaccine Link, U.S. Federal Court Declares MMR Vaccine Caused Autism in a Young Boy 2Health News:Coalition to Protect Senior Care Praises Bipartisan House Effort to Protect Seniors' Nursing Home Care, LTC Workforce 2Health News:New tool guides doctors to save cancer patients' fertility 2Health News:New tool guides doctors to save cancer patients' fertility 3
... Super-Sect is a single-use device that ... minimal thermal spread and vapor sealing ... It can be used for resection ... tumor. It is also an excellent ...
... minimally invasive treatment for prostate and renal ... use, SeedNet provides optimum accuracy, efficiency and ... is the new generation in cryotherapy for ... SeedNet system, produce iceballs of extreme sub-zero ...
Thermal Cautery, Reusable Base Unit. Burns at approximately 1200C (2200 F), non-sterile base unit with 1 non-sterile tip, 1 set single-use batteries. The two (2) AA batteries are replaceable (alkalin...
... 2201 is ideal for applications such ... of heat. , ,The autoclavable handpiece ... of reusable thermal cautery electrodes, allowing ... to perform a wide variety of ...
Medicine Products: